A trial of a plant-based COVID-19 vaccine conducted by GSK and Medicago shows an overall 71% efficacy against disease caused by the predominant SARS-CoV-2 variants of concern observed during most of 2021, and 75% efficacy specifically against disease caused by Delta. The study excludes the Omicron variant, which was not in circulation at the time of the clinical trials.
A trial of plant-based COVID-19 vaccine conducted by GSK and Medicago shows 71% efficacy against all variants of SARS-CoV-2 except Omicron and 75% efficacy against COVID-19.
A trial of aplant-based COVID-19 vaccine conducted by GSK and Medicago shows 71% efficacy against all variants of SARS-CoV-2 except Omicron and 75% efficacy against COVID-19.
A trial of a plant-based COVID-19 vaccine conducted by GSK and Medicago shows anoverall71% efficacy against diseasecausedbythepredominant SARS-CoV-2 variantsofconcernobservedduringmostof2021,and 75% efficacy specificallyagainst diseasecausedbyDelta.ThestudyexcludestheOmicronvariant,whichwasnotincirculationatthetimeoftheclinicaltrials.